Onclive Team

New collaboration to publicize advances in cancer research and treatment.

City of Hope is offering an interactive educational conference for oncologists, hematologists and oncology nurses to learn about the latest advances in bone marrow transplants, as well as the treatment of leukemia, lymphoma and myeloma.

Rutgers Cancer Institute of New Jersey to train the next generation of cancer researchers.

Saad Usmani, MD, discusses newly approved treatments for patients with multiple myeloma, as well as combination therapies currently being investigated in clinical trials.

David Reardon, MD, discusses the ReACT study and the potential of rindopepimut and other immunotherapy agents for the treatment of patients with brain cancers, specifically glioblastoma.

Keith T. Flaherty, MD, discusses molecular testing issues and the use of combined BRAF/ MEK inhibition in patients with advanced/metastatic melanoma.

Philip W. Kantoff, MD, who has made many contributions in prostate cancer research at the laboratory and leadership levels, was honored in the Genitourinary Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Howard A. “Skip” Burris III, MD, offers his views on key developments in the oncology field.

S. Vincent Rajkumar, MD, discusses a trial of bortezomib, lenalidomide, and dexamethasone versus lenalidomide plus dexamethasone in patients with previously untreated multiple myeloma.

Treatment with the combination of the CD20 inhibitor obinutuzumab and the BCL-2 inhibitor venetoclax was tolerable and demonstrated promising signs of efficacy for elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.

Although ovarian cancer remains a formidable challenge in the United States, therapeutic advances achieved during the past several years have provided specialists in gynecologic malignancies with more options than ever for treating patients.

Amid an expansion of therapeutic options for men with advanced prostate cancer, evidence is building that introducing recently developed agents and regimens earlier in the treatment timeline can benefit patients in several disease settings.

Clinical trials are now assessing how to best use radium-223 (Xofigo) in combination with androgen inhibitors, following the rapid approval of several agents for men with castration-resistant prostate cancer.

The FDA has granted an orphan drug designation to the multi-epitope folate receptor alpha (FRα) vaccine TPIV 200 as a treatment for patients with ovarian cancer.

Jimmie C. Holland, MD, whose emphasis on patients’ psychosocial needs helped humanize cancer care, was honored in the Supportive Care category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.

Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.

More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.

Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.

A Yale Cancer Center study published recently in the Journal of Clinical Oncology found that among minority women treated with early chemotherapy, black women fare worse than the other groups.

In a matter of 15 days, 3 new drugs have been approved for myeloma, namely daratumumab, ixazomib and elotuzumab.

Kenneth C. Anderson, MD, has helped transform multiple myeloma from an essentially untreatable disease to a chronic condition. He was honored in the Myeloma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group has launched to honor leaders in the field.

Experts discuss developments in CLL, myeloma, and Hodgkin lymphoma.

International study co-led by Dr. Antoni Ribas finds vemurafenib and cobimetinib extend lives and decrease risk of side effects in men and women with melanoma.

CEO and physician James Bianco, a Bronx native and Mount Sinai alumnus, establishes endowment to address area of cancer with unmet need to bring more effective therapies to patients.

Strategic Alliance Partnership will strengthen outreach to cancer patients.

Ponatinib is effective against the T315I mutation, which is a leading cuase of resistance, and has shown sustainable responses in patients with Ph+ acute lymphoblastic leukemia.

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses results seen with anti–PD-1/PD-L1 treatments in lung cancer.